278 related articles for article (PubMed ID: 21297009)
1. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
3. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
4. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
5. Natural killer T cells from interleukin-4-deficient mice are defective in early interferon-gamma production in response to alpha-galactosylceramide.
Togashi Y; Chamoto K; Wakita D; Tsutsumi N; Iwakura Y; Matsubara N; Kitamura H; Nishimura T
Cancer Sci; 2007 May; 98(5):721-5. PubMed ID: 17359285
[TBL] [Abstract][Full Text] [Related]
6. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
7. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
8. Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model.
Fujita H; Teng A; Nozawa R; Takamoto-Matsui Y; Katagiri-Matsumura H; Ikezawa Z; Ishii Y
J Immunol; 2009 Jul; 183(1):254-60. PubMed ID: 19542437
[TBL] [Abstract][Full Text] [Related]
9. Role of marginal zone B lymphocytes in invariant NKT cell activation.
Bialecki E; Paget C; Fontaine J; Capron M; Trottein F; Faveeuw C
J Immunol; 2009 May; 182(10):6105-13. PubMed ID: 19414762
[TBL] [Abstract][Full Text] [Related]
10. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
Sasakawa A; Tatsumi T; Takehara T; Yamaguchi S; Yamamoto M; Ohkawa K; Miyagi T; Hayashi N
J Hepatol; 2009 Jun; 50(6):1155-62. PubMed ID: 19376606
[TBL] [Abstract][Full Text] [Related]
11. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
[TBL] [Abstract][Full Text] [Related]
12. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis.
Bharhani MS; Chiu B; Na KS; Inman RD
Int Immunol; 2009 Jul; 21(7):859-70. PubMed ID: 19477915
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
14. Effects of cyclosporin A on the activation of natural killer T cells induced by alpha-galactosylceramide.
Kajiwara T; Tomita Y; Okano S; Iwai T; Yasunami Y; Yoshikai Y; Nomoto K; Yasui H; Tominaga R
Transplantation; 2007 Jan; 83(2):184-92. PubMed ID: 17264815
[TBL] [Abstract][Full Text] [Related]
15. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells.
Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K
Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226
[TBL] [Abstract][Full Text] [Related]
16. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
17. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro analyses of α-galactosylceramide uptake by conventional dendritic cell subsets using its fluorescence-labeled derivative.
Ushida M; Iyoda T; Kanamori M; Watarai H; Takahara K; Inaba K
Immunol Lett; 2015 Dec; 168(2):300-5. PubMed ID: 26481266
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
20. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]